Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group Trial
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes who have undergone percutaneous coronary intervention
- Registration Number
- JPRN-UMIN000026630
- Lead Sponsor
- Dokkyo medical university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria were (1) type 1 diabetes, (2) severe complications of diabetes (3) hypersensitivity to the components of dulaglutide or luseogliflozin (4) severe liver, renal dysfunction (5) severe heart failure (NYHA 3,4) (6) pregnant or nursing women and those who might be pregnant (7) Familial Hypercholesterolemia: FH (8) Treatment with PCSK-9 inhibitor (9) any patients whom the investigators judgd to be inappropriate for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in percent atheroma volume for 12 months during the treatment from baseline to study completion.
- Secondary Outcome Measures
Name Time Method